« Back to Glossary Index

A stable form of the antioxidant coenzyme Q10, the most prevalent antioxidant naturally found in the body. It neutralizes free radicals and protects the skin from UV-induced reactive oxidative species, but causes allergic reactions in some users.

Idebenone (Wikipedia)
Systematic (IUPAC) name
Clinical data
Trade names Catena, Raxone, Sovrima
AHFS/ International Drug Names
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability <1% (high first pass effect)
Protein binding >99%
Biological half-life 18 hours
Excretion Urine (80%) and feces
CAS Number 58186-27-9 YesY
ATC code N06BX13 (WHO)
PubChem CID 3686
ChemSpider 3558 YesY
KEGG D01750 YesY
Chemical data
Formula C19H30O5
Molar mass 338.439 g/mol

Idebenone (pronounced eye-deb-eh-known, trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe, but it is approved for the treatment of Leber's hereditary optic neuropathy (LHON) in Europe.

Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10).

« Back to Glossary Index